Singapore markets closed

Nuwellis, Inc. (NUWE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2523-0.0222 (-8.09%)
At close: 04:00PM EDT
0.2440 -0.01 (-3.29%)
After hours: 07:00PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy

    MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced a new purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the U.S. Nuwellis has a successful history of collaborating with individual member hospitals within the IDN on Aquadex utilization. This new network-wide agreement signifies a broader commitment to providing advanced ul

  • GlobeNewswire

    Nuwellis, Inc. Announces First Quarter 2024 Financial Results

    MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. Highlights: Revenue of $1.9 million, a 2% increase over the prior-year period.Consumables sales, representing 82% of total revenue, grew 11% year-over-year.Pediatric revenue growth of 40% year over year led by a 54% increase in consumable sales.Gross m

  • GlobeNewswire

    Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

    MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian™. This patent strengthens Nuwellis' intellectual property portfolio and paves t